Form 10-Q UNITED THERAPEUTICS Corp For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
United Therapeutics Corp. (UTHR) PT Raised to $344 at Ladenburg Thalmann
October 31, 2024 7:04 AM EDTLadenburg Thalmann analyst Matthew Kaplan raised the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $344.00 (from $319.00) while maintaining a Neutral rating.
The analyst comments "3Q24 results. Total revenues for 3Q24 were $748.9 million, higher than our estimate of $746.5 million. The revenue increase in 3Q24 ($748.9... More
